GlassScriptPhysician profile
Wendy M Vick
NPI 1093884371
$2,584.61
in general payments reported to CMS, 2019-2025
27 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $963 · 2023: $726 · 2024: $523 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $389.08 | 2022-2024 | Xarelto |
| Amgen INC. | $265.72 | 2022-2024 | Repatha |
| Abbott Laboratories | $263.60 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Mitraclip |
| Novartis Pharmaceuticals Corporation | $192.73 | 2022-2023 | |
| Philips North America LLC | $175.48 | 2022-2025 | Ecc Solutions, Mcot, (Ck4) Mcot |
| Novo Nordisk INC | $151.19 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $149.11 | 2024-2025 | Lifevest |
| Pfizer INC. | $135.33 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $114.12 | 2022-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $99.45 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $82.74 | 2022-2024 | Farxiga |
| Abiomed | $72.79 | 2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.83 | 2022-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $61.12 | 2022 | |
| Cmp Pharma, INC. | $58.38 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $44.23 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $38.30 | 2022-2025 | Uptravi, Opsumit |
| Astellas Pharma US INC | $31.74 | 2022 | |
| Sanofi-Aventis U.S. LLC | $30.77 | 2023 | |
| Daiichi Sankyo INC. | $27.83 | 2024 | Injectafer |
| Cvrx, INC. | $23.56 | 2023 | Barostim Neo System |
| Vital Connect, INC | $21.88 | 2023 | Vitalpatch Rtm |
| Angiodynamics, INC. | $21.17 | 2022 | |
| Inogen, INC. | $19.50 | 2022 | |
| Terumo Medical Corporation | $18.34 | 2025 | Azur Cx Detachable, Angio-Seal |
| Scpharmaceuticals INC. | $15.27 | 2023 | |
| Zoll Respicardia, INC. | $11.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Vick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.